2026-06-14T03:32:22Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/52252025-04-04T09:10:00Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Dominguez, Fernando
author
Ramos, Antonio
author
Bouza, Emilio
author
Munoz, Patricia
author
Valerio, Maricela C.
author
Carmen Farinas, M.
author
de Berrazueta, Jose Ramon
author
Zarauza, Jesus
author
Pericas Pulido, Juan Manuel
author
Carlos Pare, Juan
author
de Alarcón, Arístides
author
Sousa, Dolores
author
Rodriguez Bailon, Isabel
author
Montejo-Baranda, Miguel
author
Noureddine, Mariam
author
Garcia Vazquez, Elisa
author
Garcia-Pavia, Pablo
funder
Instituto de Salud Carlos III
2017-10-30T13:15:45Z
2017-10-30T13:15:45Z
2016
Medicine (Baltimore). 2016; 95(26):e4008
10.1097/MD.0000000000004008
1536-5964
0025-7974
Medicine
27368014
http://hdl.handle.net/20.500.12105/5225
Infective endocarditis (IE) complicating hypertrophic cardiomyopathy (HCM) is a poorly known entity. Although current guidelines do not recommend IE antibiotic prophylaxis (IEAP) in HCM, controversy remains.This study sought to describe the clinical course of a large series of IE HCM and to compare IE in HCM patients with IE patients with and without an indication for IEAP.Data from the GAMES IE registry involving 27 Spanish hospitals were analyzed. From January 2008 to December 2013, 2000 consecutive IE patients were prospectively included in the registry. Eleven IE HCM additional cases from before 2008 were also studied. Clinical, microbiological, and echocardiographic characteristics were analyzed in IE HCM patients (n = 34) and in IE HCM reported in literature (n = 84). Patients with nondevice IE (n = 1807) were classified into 3 groups: group 1, HCM with native-valve IE (n = 26); group 2, patients with IEAP indication (n = 696); group 3, patients with no IEAP indication (n = 1085). IE episode and 1-year follow-up data were gathered.One-year mortality in IE HCM was 42\% in our study and 22\% in the literature. IE was more frequent, although not exclusive, in obstructive HCM (59\% and 74\%, respectively). Group 1 exhibited more IE predisposing factors than groups 2 and 3 (62\% vs 40\% vs 50\%, P<0.01), and more previous dental procedures (23\% vs 6\% vs 8\%, P<0.01). Furthermore, Group 1 experienced a higher incidence of Streptococcus infections than Group 2 (39\% vs 22\%, P<0.01) and similar to Group 3 (39\% vs 30\%, P = 0.34). Overall mortality was similar among groups (42\% vs 36\% vs 35\%, P = 0.64).IE occurs in HCM patients with and without obstruction. Mortality of IE HCM is high but similar to patients with and without IEAP indication. Predisposing factors, previous dental procedures, and streptococcal infection are higher in IE HCM, suggesting that HCM patients could benefit from IEAP.
eng
antibiotic prophylaxis
endocarditis
hypertrophic cardiomyopathy
BACTERIAL-ENDOCARDITIS
PROPHYLAXIS
PREVENTION
DIAGNOSIS
RECOMMENDATIONS
GUIDELINES
Infective endocarditis in hypertrophic cardiomyopathy: A multicenter, prospective, cohort study
journal article
URL
https://repisalud.isciii.es/bitstreams/ca01f0cd-9b44-4be7-ba8c-c18b7a0cdf15/download
File
MD5
b9388cd4667ad22585ebebcba63fb91e
347049
application/pdf
InfectiveEndocarditisInHypertrophicCardiomyopathy_2016
URL
https://repisalud.isciii.es/bitstreams/db3272a4-2da0-4f73-a3d9-84cb8a5fc348/download
File
MD5
3be15151abeefc98b4c15375a47dce28
38551
text/plain
InfectiveEndocarditisInHypertrophicCardiomyopathy_2016.txt